Dyspepsia, Gastroesophageal Refluxdisease, Ulcer
Conditions
Keywords
Protonpumpinhibitors, withdrawal, longterm treatment, dyspepsia, functional dyspepsia, gastrooesophageal reflux, upper endoscopy
Brief summary
The primary purpose of the study is to determine the effect of esomeprazole compared to placebo in patients from general practice who have previously been treated with proton-pump-inhibitors (PPI) and who have no upper endoscopic findings.
Detailed description
The majority of patients with dyspepsia are treated in primary care with acid-suppressive therapy for shorter or longer periods of time on the assumption that the patients´ symptoms are related to the production of acid in the stomach. In about half of the dyspeptic patients there is no structural or biochemical explanation for their symptoms. These patients suffer from functional dyspepsia. Treatment with proton-pump-inhibitors is effective in treating patients with gastroesophageal refluxdisease or ulcers. It is however controversial if acid-suppressive treatment is effective in the large group of patients with functional dyspepsia. Previous studies have shown no or very modest effect with a very high placeboresponse rate of 40-50%. In primary care patients with upper abdominal symptoms are often treated with PPI as a diagnostic tool. If the treatment is effective continued or repeated treatment with PPI is often favored. However some of the patients must experience the abovementioned placebo-effect. These patients may end up being treated with PPI long-term on uncertain indication. We wish to investigate the consequences of withdrawing treatment with PPI in patients from general practice who have previously been treated long-term. An upper endoscopy is performed in patients who experience upper abdominal symptoms after withdrawal of treatment.If the endoscopy is normal patients are randomised to 1 week treatment with either esomeprazole or placebo.
Interventions
DRUGesomeprazole
Sponsors
Glostrup University Hospital, Copenhagen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Treatment with PPI in at least 4 months out of the preceding 12. * Use of PPI in the preceding 10 out of 30 days before inclusion * Age above 18 years
Exclusion criteria
* Erosive Esophagitis * PPI-treatment as prophylaxis against gastrointestinal bleeding * PPI-treatment as prophylaxis against ulcers * PPI-treatment as prophylaxis because of NSAID-treatment * Pregnant or lactating women * Previous upper GI surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of the effect of treatment in one week with esomeprazole and placebo measured as symptomscore in patientdiary. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fraction of patients who are willing to withdraw treatment with PPI | — |
| Fraction of patients who experience symptoms after withdrawal of treatment. | — |
| Investigators and patients ability to distinguish between active and placebo treatment | — |
| Length of time from withdrawal till symptoms arise | — |
| Correlation between levels of gastrin and CgA and time till symptoms arise | — |
| Description of endoscopic findings in patients who have previously been treated with PPI long-term and who after withdrawal are symptomatic | — |
Countries
Denmark
Contacts
Primary ContactChristina Reimer, MD
Outcome results
None listed